<DOC>
	<DOCNO>NCT02699606</DOCNO>
	<brief_summary>The primary purpose study evaluate objective response rate ( ORR ) per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 erdafitinib molecularly-defined subset Asian participant non-small-cell lung cancer ( NSCLC ) , urothelial cancer , esophageal cancer cholangiocarcinoma .</brief_summary>
	<brief_title>A Study Evaluate Clinical Efficacy JNJ-42756493 ( Erdafitinib ) , A Pan-Fibroblast Growth Factor Receptor ( FGFR ) Tyrosine Kinase Inhibitor , In Asian Participants With Advanced Non-Small-Cell Lung Cancer , Urothelial Cancer , Esophageal Cancer Or Cholangiocarcinoma</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multicenter , phase 2 study evaluate clinical efficacy , safety pharmacokinetics erdafitinib Asian participant advance NSCLC , urothelial cancer , esophageal cancer cholangiocarcinoma .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Pathologically cytologically confirm , advanced refractory tumor ( restriction total number line prior therapy , participant receive least 1 line anticancer therapy [ per local standard care ] ) : Squamous nonsquamous nonsmallcell lung cancer ( NSCLC ) , esophageal cancer , urothelial cancer cholangiocarcinoma Participants must meet follow molecular eligibility criterion ( diagnosed central local laboratory use either tumor tissue base assay , must indicate : least one follow ) : ) fibroblast growth factor receptor ( FGFR ) gene translocation b ) FGFR gene mutation c ) Participants evidence FGFR pathway activation potential target/pathway inhibit erdafitinib may also consider allow enrollment support emerge biomarker data . The presence measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST , Version 1.1 ) Criteria , document disease progression define RECIST ( Version 1.1 ) baseline Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 Female participant ( child bear potential sexually active ) male participant ( partner child bear potential ) must use medically acceptable method birth control . Male participant must use highly effective birth control measurement sexually active must donate sperm Adequate bone marrow , liver , renal function within 14 day prior Day 1 Cycle 1 predose Cycle 1 Chemotherapy , target therapy , immunotherapy , treatment investigational anticancer agent within 2 week least 5 halflives drug whichever longer maximum 4 week first administration study drug . Localized palliative radiation therapy ( include radiation target lesion ) ongoing luteinizing hormonereleasing hormone ( LHRH ) agonists , bisphosphonates denosumab , permit Participants persistent phosphate great ( &gt; ) upper limit normal ( ULN ) Screening ( within 14 day prior Day 1 Cycle 1 predose Cycle 1 ) despite medical management phosphate level Participants take medication know significant risk cause QTc prolongation Torsades de Pointes . Participants discontinued medication must washout period least 5 day least 5 halflives drug ( whichever longer ) prior first dose study drug Left ventricular ejection fraction ( LVEF ) less ( &lt; ) 50 % assess echocardiography ( multigated acquisition [ MUGA ] ) perform Screening Uncontrolled intercurrent illness include , limited , poorly control hypertension diabetes , ongoing active infection require antibiotic , psychiatric illness , risk gastrointestinal perforation per investigator ' assessment Received prior selective FGFR inhibitor treatment RET inhibitor treatment , respectively accord biomarker prescreening result , participant know allergy , hypersensitivity , intolerance Erdafitinib excipients Any corneal retinal abnormality likely increase risk eye toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tumor</keyword>
	<keyword>Fibroblast Growth Factor Receptor ( FGFR )</keyword>
	<keyword>Non-Small Cell Lung Cancer ( NSCLC )</keyword>
	<keyword>Erdafitinib</keyword>
	<keyword>Urothelial Cancer</keyword>
	<keyword>Esophageal Cancer</keyword>
	<keyword>Cholangiocarcinoma</keyword>
</DOC>